Compare SURG & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SURG | NOTV |
|---|---|---|
| Founded | 2006 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.6M | 29.9M |
| IPO Year | N/A | 1997 |
| Metric | SURG | NOTV |
|---|---|---|
| Price | $1.81 | $0.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $9.50 | $3.00 |
| AVG Volume (30 Days) | 133.3K | ★ 1.6M |
| Earning Date | 11-12-2025 | 12-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $50,372,555.00 | ★ $513,024,000.00 |
| Revenue This Year | $7.13 | $6.26 |
| Revenue Next Year | $122.51 | $45.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4.54 |
| 52 Week Low | $1.05 | $0.66 |
| 52 Week High | $3.47 | $6.48 |
| Indicator | SURG | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 32.06 | 36.67 |
| Support Level | $1.66 | $0.84 |
| Resistance Level | $2.01 | $0.95 |
| Average True Range (ATR) | 0.11 | 0.12 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 25.32 | 39.36 |
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.